Product Pipeline

IND Code Dosage Form Features Indications Development Development
Locations Stage
TAS-114 Oral dUTPase inhibitor Non-small cell lung cancer (NSCLC) Japan Phase II
US Phase II
Europe Phase II
TAS-115 Oral Multi-kinase inhibitor Prostate cancer Japan Phase II
Idiopathic pulmonary fibrosis Japan Phase II
Osteosarcoma Japan Phase III
TAS-116 Oral HSP90 inhibitor Gastrointestinal stromal tumor (GIST) Japan Phase III
Solid tumors US Phase I
Europe Phase I
TAS-117 Oral 　 Solid tumors Japan Phase I
TAS-120
 Oral FGFR inhibitor　 Cholangiocarcinoma Japan Phase Ⅱ
US Phase Ⅱ
Europe Phase Ⅱ
Breast cancer US Phase Ⅱ
Europe Phase Ⅱ
FGFR aberrations cancer Japan Phase Ⅱ
US Phase Ⅱ
Europe Phase Ⅱ
TAS0313 Injection Peptide vaccine Urothelial cancer Japan Phase Ⅱ
TAS3681 Oral 　 Prostate cancer US Phase I
Europe Phase I
TAS0728 Oral 　 Solid tumors US Phase Ⅰ/Ⅱ
Europe Phase Ⅰ/Ⅱ
TAS0612 Oral Solid tumors US

Phase Ⅰ
Europe Phase Ⅰ
ET-743 Injection Ovarian cancer Japan Phase I
Pro-NETU Injection NK1 receptor antagonist Chemotherapy-induced nausea and vomiting (CINV) Japan Phase III
TAS-205 Oral PGD synthase inhibitor Duchenne muscular dystrophy(DMD) Japan Phase III
TAS5315 Oral BTK inhibitor Rheumatoid arthritis(RA) Japan Phase II
TAC-302 Oral 　 Detrusor underactivity with overactive bladder Japan Phase II
TAS-303 Oral Selective norepinephrine
reuptake inhibitor		 Stress urinary incontinence Japan Phase II

As of Dec. 31, 2020